Iterum Therapeutics plc
ITRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $390 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $20 | $696 | $342 | $0 |
| Gross Profit | $370 | -$696 | -$342 | $0 |
| % Margin | 94.9% | – | – | – |
| R&D Expenses | $1,261 | $649 | $591 | $1,299 |
| G&A Expenses | $0 | $4,184 | $2,777 | $2,117 |
| SG&A Expenses | $6,491 | $4,184 | $2,777 | $2,117 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $254 |
| Operating Expenses | $7,752 | $4,833 | $3,368 | $3,670 |
| Operating Income | -$7,382 | -$5,529 | -$3,710 | -$3,670 |
| % Margin | -1,892.8% | – | – | – |
| Other Income/Exp. Net | -$1,465 | -$921 | -$1,121 | -$2,887 |
| Pre-Tax Income | -$8,847 | -$6,450 | -$4,831 | -$6,557 |
| Tax Expense | $132 | $59 | $60 | $25 |
| Net Income | -$8,979 | -$6,509 | -$4,891 | -$6,582 |
| % Margin | -2,302.3% | – | – | – |
| EPS | -0.2 | -0.16 | -0.14 | -0.25 |
| % Growth | -25% | -14.3% | 44% | – |
| EPS Diluted | -0.2 | -0.16 | -0.14 | -0.25 |
| Weighted Avg Shares Out | 45,802 | 39,935 | 34,060 | 19,699 |
| Weighted Avg Shares Out Dil | 45,802 | 39,935 | 34,060 | 19,699 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $133 | $0 | $0 |
| Interest Expense | $441 | $449 | $534 | $874 |
| Depreciation & Amortization | $355 | $351 | $349 | $261 |
| EBITDA | -$8,051 | -$5,650 | -$3,948 | -$5,422 |
| % Margin | -2,064.4% | – | – | – |